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prostate ultrasound images with either a Foley or gel were fused 
and analyzed. The catheter tends to take a path of least 
curvature and is thus located in the anterior urethra. At mid-
prostate the difference is most pronounced with the posterior 
edge of the catheter located up to 7 mm anterior to the posterior 
aspect of the gel-filled urethra. Urethra V115% was higher when 
the urethra was defined with gel. Median V115% was 0 cc (0-0.03) 
with catheter compared to 0.03 cc (0-0.53) with gel (p = 0.02) 
and translated to a median V115% of 0% (0-2.14) versus 3.23% (0-
20.95) (p = 0.003), respectively. Only one patient when analyzed 
with the gel had a V118% > 10%(16.6%) and three had a V125% > 
0 cc (p = 0.31). The urethral volume was 1.4 cc (1.04-1.85) using 
the 6mm circle and was 1.22 cc(0.7-2.53) when using aerated gel 
(p = 0.522). At the prostate base and apex the smaller diameter 
of the urethra makes visualization with gel alone difficult. 
Conclusions: Using a Foley catheter for urethral identification 
and dose prescription underestimates the dose that is actually 
received by some patients. Urethral curvature differs from the 
Foley catheter, especially at mid gland where the catheter rides 
anteriorly. A standard 6 mm circle does not represent the entire 
urethral volume. Although we have not observed unexpected 
toxicity, we will continue to monitor actual urethral dose to 
correlate with toxicity in future patients. In the meantime, use 
of a catheter is the most reliable means of visualizing the entire 
length of the prostatic and membranous urethra. Consideration 
could be given to expanding the 6 mm circle in the posterior 
direction in mid-gland. 
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Purpose: To evaluate long-term biochemical control (bRFR) and 
radiation toxicity for men with localized prostate cancer treated 
with two moderately hypofractionated IG-IMRT regimens. 
Methods and Materials: Eligible consenting men with T1c-T3a Nx 
M0 prostate cancer were enrolled in a Phase II trial and received 
IG-IMRT to a risk-adapted volume that included prostate +/- 
seminal vesicles at 3 Gy per fraction, 5 days per week in 
sequential cohorts to a total dose of either 60 Gy or 66 Gy. Late 
gastrointestinal (GI) and genitourinary (GU) toxicity were 
recorded at each follow up using the Radiation Therapy Oncology 
Group criteria and biochemical failure was scored using the PSA 
nadir+2 criteria. Outcome estimates were calculated using the 
Kaplan-Meier method and log rank test. Early stopping rules 
terminated accrual to the 66 Gy cohort due to excessive Grade 
3-4 late toxicity. 
Results: Ninety-six men received 6 0Gy and 28 received 66 Gy. 
Androgen deprivation therapy (3-36 months duration) was used 
in 10% of men in both cohorts. For each cohort, the median age 
was 71 years (60 Gy) and 70 years (66 Gy). Low or intermediate-
risk presentation was respectively 27% and 65% (60 Gy) and 25% 
and 71% (66 Gy). Median follow up was 128 months (60 Gy) and 
108 months (66 Gy). The five- and eight-year bRFR for 60 Gy and 
66 Gy were respectively 83% and 67% versus 88.5% and 73.4% (p 
= 0.224). For each cohort, five (60 Gy) and one (66 Gy) subjects 
died from disease. Overall five- and eight-year cumulative late 
Grade 1-4 GI toxicity for 60 Gy versus 66 Gy were respectively 
21.2% and 21.2% versus 44.6% and 48.9% (p = 0.004). Cumulative 
late Grade 1-4 GU toxicities were respectively 23.8% and 32.8% 
versus 40.4% and 51.4% (p = 0.048). Cumulative five- and eight-
year late Grade 3-4 GI toxicity for 60 Gy and 66 Gy were 
respectively 1.1% and 1.1% versus 11.5% and 11.5% (p = 0.01). 
Cumulative five- and eight-year late Grade 3-4 GU toxicity for 60 
Gy and 66 Gy were respectively 0 and 1.5% versus 3.7% and 3.7% 
(p = 0.41). At last follow up in the 60 Gy cohort there were no 
Grade ≥ 3 late GI toxicities and one Grade 3 late GU toxicity. In 
the 66 Gy cohort there was one Grade 4 late GI toxicity and one 
Grade 4 late GU toxicity. 
Conclusions: Moderate hypofractionation to 60 Gy was 
associated with modest late toxicity and provided excellent five-
year bRFR for our patients, although failures continued to be 
observed with subsequent follow up. Dose escalation to 66 Gy 
was associated with significantly worse late GI and GU toxicity 
without an apparent improvement in bRFR. 
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Purpose: To determine the impact of pre-treatment interstitial 
lung disease (ILD) on radiation pneumonitis and overall survival 
(OS) in patients treated with lung SBRT. 
Methods and Materials: Patients treated with lung SBRT 
between October 2004 and July 2015 at our institution were 
included. Pre-treatment CT scans were reviewed by experienced 
thoracic radiologists and interstitial changes including ground 
glass opacities (GGO), reticulations and honeycombing were 
scored and involvement to the nearest 5% was used to calculate 
Washko and Kazerooni scores. Radiation pneumonitis (RP) was 
prospectively documented using the CTCAE V4.0 criteria. Pre-
treatment imaging characteristics, lung and heart dose 
parameters and clinical variables including smoking status and 
pulmonary function were assessed by univariate (UVA) and 
multivariate analysis (MVA). OS was assessed by log rank test and 
impact of ILD on overall survival was assessed by Cox regression. 
Results: Five hundred and forty-two patients were assessed with 
56 having evidence of interstitial changes on pre-treatment 
scans. These included 12 cases of usual interstitial pneumonia 
(UIP), 18 cases of possible UIP, nine cases of non-specific 
interstitial pneumonia and 17 cases of age-related reticulations 
thought to be unrelated to ILD. RP was significantly higher in the 
39 patients with ILD (Grade ≥ 2 20.5% versus 5.8%, p < 0.01; Grade 
≥ 3 10.3% versus 1.0%, p < 0.01). Of the three cases of Grade 5 
RP observed in our series, two had imaging features of ILD. On 
UVA, radiographic evidence of ILD, Washko score, lung 
parameters (V5/V10/V15/V20/mean lung dose) and performance 
status were significant predictors of Grade ≥ 2 RP. Age-related 
reticulations were not associated with increased toxicity. On 
MVA, ILD (OR 5.18, p < 0.01) and mean lung dose (OR 1.003, p < 
0.01) were predictors of RP. ILD did not significantly affect OS 
on UVA or MVA. Median survival was 26.5 months in the ILD cohort 
and 36.6 in the ILD negative cohort (p = 0.09). 
Conclusions: Radiographic evidence of ILD is a significant risk 
factor for RP in patients treated with lung SBRT, but did not 
impact OS. CT scans should be reviewed for evidence of ILD prior 
to SBRT and involvement of respirology for management is 
essential. If ILD patients are treated with SBRT, they should be 
monitored closely for RP. 
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Purpose: Real-time transrectal ultrasound (TRUS) image 
guidance for prostate high dose-rate brachytherapy (HDR-BT) 
